Follow us for updates
© 2022
Read the Story →

Sinopharm Seeks Emergency Authorization for COVID Vaccine in PH

Fourth to receive EUA?
by Arianne Merez
Mar 1, 2021
Photo/s: Shutterstock

China's Sinopharm is applying for emergency use authorization for its COVID-19 vaccine in the Philippines, Malacañang said Monday as the country rolled out its mass immunization program.

Sinopharm has filed its application with the local Food and Drug Administration for evaluation, Presidential Spokesperson Harry Roque said.

"It has been filed. They have already filed with the FDA an application for EUA for Sinopharm vaccine," Roque said in a press briefing.


First Vaccine Shot in the PH is Given, One Year Since COVID Quarantines

WATCH: Philippines' First Official COVID Vaccine is Given

But the DOH said it received information from FDA Director General Eric Domingo that the Chinese firm has yet to file an application for EUA.

Granting an EUA to a vaccine would expedite its availability to the people who need it the most but it is not a license to sell the drugs commercially.

In the case of the COVID-19 pandemic, the Philippine government is rushing to make vaccines available to the most vulnerable to the virus: medical frontliners, and the elderly.

Continue reading below ↓

So far, the Philippines has authorized three vaccines for emergency use -- Pfizer and BioNTech's, AstraZeneca's, and Sinovac's.


Explained: How COVID Vaccines Get Fast-Tracked for Emergency Use

Continue reading below ↓
Recommended Videos
Latest Headlines
Read Next
Recent News
Appointment announced a day before Marcos' inauguration.
More time for K-drama, books, and mornings without alarms.
With the reopening of several local destinations, this app has never been more timely.
You can participate in person and virtually.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.